Coya’s focus is on generating safe, tolerable, and efficacious therapeutics that minimally burden the patient and caregiver and exponentially improve outcomes over the current standard of care
A 5-minute infusion in an outpatient facility with patients leaving the office within 1 – 2 hours. Proprietary technology enables multiple infusions over the course of the year
A limiting feature of Tregs has been their instability and inability to cryopreserve for maintenance therapy. Coya has perfected this process allowing a patient to be treated long term with highly viable and neuroprotective cells
Dr. Stanley Appel “Patients with neurodegenerative diseases are in desperate need of transformative therapeutic options; harnessing the neuro-protective effects of Treg cell therapy shows great promise in unlocking a new treatment paradigm and will enable us to revolutionize care for patients with devastating neurodegenerative diseases.”
Clinical Trials
Check back regularly for updates on upcoming trials.CLINICALTRIALS.GOV
